A New Immune-Biochemical Study To Identify Indicators Of The Response Of Infertile Polycystic Ovary Syndrome Patients To Metformin Treatment
June 2025
in “
International Journal of Environmental Sciences
”
TLDR CLEC10A and interleukin-42 can help identify PCOS patients' response to Metformin treatment.
This study investigated immune-biochemical indicators in 90 women with PCOS, divided into three groups: those treated for infertility, untreated PCOS patients, and a healthy control group. Using the Sandwich-ELISA technique, significant differences in integrin, CLEC10A, and interleukin-42 levels were found between the groups. Notably, CLEC10A and interleukin-42 levels were elevated in untreated PCOS patients compared to those treated with Metformin. Strong correlations were observed between these markers, with Metformin treatment showing a negative correlation between integrin and interleukin-42, and CLEC10A and interleukin-42. The study concluded that CLEC10A and interleukin-42 are effective in differentiating between Metformin-treated and untreated PCOS patients, with high sensitivity and specificity, suggesting their potential as diagnostic tools.